GNBT,
Generex Biotechnology Announces Glucose RapidSpray(TM) Product to Be Available at Shoppers Drug Mart(R)
Wednesday October 4, 9:40 am ET
TORONTO--(MARKET WIRE)--Oct 4, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that the Company's new Glucose RapidSpray™ product will be available in Shoppers Drug Mart® stores across Canada (Pharmaprix® in Québec) in late October, 2006.
ADVERTISEMENT
Shoppers Drug Mart is Canada's largest retail drug store group with more than 960 retail drug stores. With fiscal 2005 sales of $7.2 billion, Shoppers Drug Mart is the leading player in Canada's retail drugstore marketplace and is the number one provider of pharmacy products and services. Shoppers Drug Mart stores are located in prime locations in each province and two territories, making Shoppers Drug Mart stores among the most convenient retail outlets in Canada.
Glucose RapidSpray is an innovative alternative for people who require or want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation that was developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray delivers glucose directly into the mouth. Glucose RapidSpray is simple to carry and use, with no large tablets to chew or messy gels to swallow.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Contact:
Contacts:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: (800) 391-6755
or (416) 364-2551
Andrew Hellman
CEOcast, Inc.
Phone: (212) 732-4300
Dolores Naney
Rubenstein Public Relations
Phone: (212) 843-8018
Email Contact |
